Literature DB >> 31855577

Dynamic perfluorinated gas MRI reveals abnormal ventilation despite normal FEV1 in cystic fibrosis.

Jennifer L Goralski1,2,3, Sang Hun Chung4, Tyler M Glass5, Agathe S Ceppe1,2, Esther O Akinnagbe-Zusterzeel4, Aaron T Trimble1,2, Richard C Boucher1,2, Brian J Soher6, H Cecil Charles7, Scott H Donaldson1,2, Yueh Z Lee1,4.   

Abstract

We hypothesized that dynamic perfluorinated gas MRI would sensitively detect mild cystic fibrosis (CF) lung disease. This cross-sectional study enrolled 20 healthy volunteers and 24 stable subjects with CF, including a subgroup of subjects with normal forced expiratory volume in the first second (FEV1; >80% predicted, n = 9). Dynamic fluorine-19-enhanced MRI (19F MRI) were acquired during sequential breath holds while breathing perfluoropropane (PFP) and during gas wash-out. Outcomes included the fraction of lung without significant ventilation (ventilation defect percent, VDP) and time constants that described PFP wash-in and wash-out kinetics. VDP values (mean ± SD) of healthy controls (3.87% ± 2.7%) were statistically different from moderate CF subjects (19.5% ± 15.5%, P = 0.001) but not from mild CF subjects (10.4% ± 9.9%, P = 0.24). In contrast, the fractional lung volume with slow gas wash-out was elevated both in subjects with mild (9.61% ± 4.87%; P = 0.0066) and moderate CF (16.01% ± 5.01%; P = 0.0002) when compared with healthy controls (3.84% ± 2.16%) and distinguished mild from moderate CF (P = 0.006). 19F MRI detected significant ventilation abnormalities in subjects with CF. The ability of gas wash-out kinetics to distinguish between healthy and mild CF lung disease subjects makes 19F MRI a potentially valuable method for the characterization of early lung disease in CF. This study has been registered at ClinicalTrials.gov (NCT03489590).

Entities:  

Keywords:  Diagnostic imaging; Pulmonology

Mesh:

Substances:

Year:  2020        PMID: 31855577      PMCID: PMC7098716          DOI: 10.1172/jci.insight.133400

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  23 in total

1.  Morphologic and functional scoring of cystic fibrosis lung disease using MRI.

Authors:  Monika Eichinger; Daiva-Elzbieta Optazaite; Annette Kopp-Schneider; Christian Hintze; Jürgen Biederer; Anne Niemann; Marcus A Mall; Mark O Wielpütz; Hans-Ulrich Kauczor; Michael Puderbach
Journal:  Eur J Radiol       Date:  2011-03-23       Impact factor: 3.528

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

Review 3.  Magnetic resonance imaging of the lung in cystic fibrosis.

Authors:  Talissa A Altes; Monika Eichinger; Michael Puderbach
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Physiorack: an integrated MRI safe/conditional, gas delivery, respiratory gating, and subject monitoring solution for structural and functional assessments of pulmonary function.

Authors:  Ahmed F Halaweish; H Cecil Charles
Journal:  J Magn Reson Imaging       Date:  2013-10-07       Impact factor: 4.813

5.  Extending semiautomatic ventilation defect analysis for hyperpolarized (129)Xe ventilation MRI.

Authors:  Mu He; S Sivaram Kaushik; Scott H Robertson; Matthew S Freeman; Rohan S Virgincar; H Page McAdams; Bastiaan Driehuys
Journal:  Acad Radiol       Date:  2014-09-26       Impact factor: 3.173

6.  Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease.

Authors:  Mark O Wielpütz; Michael Puderbach; Annette Kopp-Schneider; Mirjam Stahl; Eva Fritzsching; Olaf Sommerburg; Sebastian Ley; Migle Sumkauskaite; Jürgen Biederer; Hans-Ulrich Kauczor; Monika Eichinger; Marcus A Mall
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

7.  A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials.

Authors:  Marcus J Couch; Robert Thomen; Nikhil Kanhere; Raymond Hu; Felix Ratjen; Jason Woods; Giles Santyr
Journal:  J Cyst Fibros       Date:  2019-03-25       Impact factor: 5.482

8.  Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients.

Authors:  Robert P Thomen; Laura L Walkup; David J Roach; Zackary I Cleveland; John P Clancy; Jason C Woods
Journal:  J Cyst Fibros       Date:  2016-07-29       Impact factor: 5.482

9.  Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.

Authors:  Lauren S Mott; Judy Park; Conor P Murray; Catherine L Gangell; Nicholas H de Klerk; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan; Peter D Sly; Stephen M Stick
Journal:  Thorax       Date:  2011-12-26       Impact factor: 9.139

10.  Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest x-ray.

Authors:  Michael Puderbach; Monika Eichinger; Julie Haeselbarth; Sebastian Ley; Annette Kopp-Schneider; Siegfried Tuengerthal; Astrid Schmaehl; Christian Fink; Christian Plathow; Matthias Wiebel; Sueha Demirakca; Frank-Michael Müller; Hans-Ulrich Kauczor
Journal:  Invest Radiol       Date:  2007-10       Impact factor: 6.016

View more
  5 in total

Review 1.  Novel imaging techniques for cystic fibrosis lung disease.

Authors:  Jennifer L Goralski; Neil J Stewart; Jason C Woods
Journal:  Pediatr Pulmonol       Date:  2021-02

2.  Reproducibility of 19 F-MR ventilation imaging in healthy volunteers.

Authors:  Benjamin J Pippard; Mary A Neal; Adam M Maunder; Kieren G Hollingsworth; Alberto Biancardi; Rod A Lawson; Holly Fisher; John N S Matthews; A John Simpson; Jim M Wild; Peter E Thelwall
Journal:  Magn Reson Med       Date:  2021-01-28       Impact factor: 4.668

Review 3.  Perfluorocarbon Emulsion Contrast Agents: A Mini Review.

Authors:  Ryan Holman; Orane Lorton; Pauline C Guillemin; Stéphane Desgranges; Christiane Contino-Pépin; Rares Salomir
Journal:  Front Chem       Date:  2022-01-10       Impact factor: 5.221

4.  Defect distribution index: A novel metric for functional lung MRI in cystic fibrosis.

Authors:  Anne Valk; Corin Willers; Kamal Shahim; Orso Pusterla; Grzegorz Bauman; Robin Sandkühler; Oliver Bieri; Florian Wyler; Philipp Latzin
Journal:  Magn Reson Med       Date:  2021-08-02       Impact factor: 3.737

5.  Comparison of single breath hyperpolarized 129 Xe MRI with dynamic 19 F MRI in cystic fibrosis lung disease.

Authors:  Andrew McCallister; Sang Hun Chung; Michael Antonacci; Margret Z Powell; Agathe S Ceppe; Scott H Donaldson; Yueh Z Lee; Rosa Tamara Branca; Jennifer L Goralski
Journal:  Magn Reson Med       Date:  2020-08-08       Impact factor: 4.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.